Archive for the 'Tumor Debulking' Category
Surgically removing as much of the tumor as possible. Also known as cytoreductive surgery in the pelvic/abdominal area.
January 2nd, 2008. Malignant peritoneal mesothelioma: treatment with maximal cytoreductive surgery plus intraperitoneal chemotherapy
Conclusion: This new approach combining complete cytoreductive surgery considerably increases the survival of patients with MPM compared with the standard treatment based on systemic chemotherapy.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Oxaliplatin (Eloxatin), Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 25th, 2007. Localised malignant pleural mesothelioma: a separate clinical entity requiring aggressive local surgery
Conclusion: Our results suggest that surgery is indicated in treating localised MPM even in T4 (diffuse chest wall involvement) tumours but pleuropneumonectomy is not necessary. These tumours seem to have a different biological behaviour compared to diffuse MPM but further research, including identification of possibly different biological markers is necessary.
Posted in Biphasic or Mixed, Epithelioid, Full Archive, Pleural, Pleurectomy/decortication, Pneumonectomy, Sarcomatoid, Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 21st, 2007. Updated treatment of peritoneal carcinomas: a review
Considering the constant increasing of diseases treatable with this procedure, more centres should be activated. The establishment of a clear policy and scientific guidelines is mandatory, in order to perform the CRS+HIPEC safely, minimizing treatment-related morbidity and mortality and maximizing the results in terms of survival and quality of life.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 17th, 2007. Aggressive Surgical Management of Peritoneal Carcinomatosis With Low Mortality in a High-Volume Tertiary Cancer Center
Conclusions: In a high-volume center with extensive experience treating peritoneal malignancies, perioperative mortality can be lowered to nearly zero, although morbidity remains high. CS-HIPEC procedures should be studied further in a controlled manner to help define their important role in the care of patients with PC.
Posted in Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 1st, 2007. Peritoneal mesothelioma presenting as an acute surgical abdomen due to jejunal perforation
Conclusions: Peritoneal mesothelioma is a rare malignancy with grim prognosis. Small bowel involvement is a poor prognostic indicator. Our case of a small bowel perforation due to direct infiltration by peritoneal mesothelioma appears to be the first reported in the English literature.
Posted in Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
October 3rd, 2007. Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?
However, the tumor grew rapidly and spread to the pleura, involved the heart, and the patient succumbed. This is to our knowledge the first report of a sarcomatous mesothelioma with bone formation from environmental exposure to mineral fibers.
Posted in Carboplatin, Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Pemetrexed (Alimta), Pericardial, Pleural, Sarcomatoid, Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 22nd, 2007. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings
We present a summary of cytologic features that, in our experience, we find to be most useful in making or excluding a diagnosis of PPM. To our knowledge, this is the first large series reporting the cytomorphologic features of PPM in peritoneal effusions, pelvic washing specimens, and infradiaphragmatic fine-needle aspiration biopsy specimens.
August 19th, 2007. Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy
In ovarian cancer the rationale for this treatment remains large but its current application is limited. Much work needs to be done to identify a proper clinical perspective on hyperthermia used with chemotherapy in patients with peritoneal surface malignancy.
July 31st, 2007. Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC)
Conclusions: MPM and WDPPM are borderline tumors capable of transformation into potentially lethal processes. Definitive tumor eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease recurrence or transition to aggressive malignancies.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Diffuse mesothelioma, Doxorubicin, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 20th, 2007. Limited cardiotoxicity after extensive thoracic surgery and intraoperative hyperthermic intrathoracic chemotherapy with doxorubicin and cisplatin
Conclusions: Early cardiotoxicity is limited after this treatment modality using substantial doses of doxorubicin and cisplatin. Hence, this study suggests that intrathoracic chemotherapy with doxorubicin and/or cisplatin may be used for primary and secondary pleural malignancies, even immediately after extensive thoracic surgery, without concern of severe early cardiotoxicity.
July 18th, 2007. Clinical results of cytoreduction and HIPEC for malignant peritoneal mesothelioma
Finally, although the intensity of therapy is considerable, once recovered, the patients appear to enjoy a good HRQOL. Although not specific for patients with MPM, 2 reports have convincingly demonstrated that HRQOL is significantly improved after HIPEC.
Posted in Chemotherapy, CT or CAT scan, Determining Efficacy, Diagnosis & Differentiation, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 11th, 2007. So13p cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma – analysis of 100 consecutive patients from a prospective database
Conclusions: CRS and PIC showed an improved survival for DMPM, as compared to historical controls. Long-term survival was associated with female gender, absence of lymph node involvement, epithelial or multicystic type and adequate cytoreduction.
Posted in Chemotherapy, Determining Efficacy, Diffuse mesothelioma, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 11th, 2007. So12p combined cytoreductive surgery and perioperative intraperitoneal chemotherapy in the treatment of peritoneal mesothelioma
Conclusion: CRS combined with PIC is a treatment option for peritoneal mesothelioma that confers improved survival, when compared with historical controls using systemic chemotherapy.
Posted in Causation, Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
March 3rd, 2007. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection
Thus, SM16 shows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated mechanism and can significantly prevent tumor recurrence after resection of bulky AB12 malignant mesothelioma tumors. These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers.
February 20th, 2007. Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia
Conclusions: Radical oncologic cytoreductive surgery combined with intraperitoneal perioperative chemotherapy provides good results with prolonged survival in selected cases, although morbidity is high. Based in our experience, biphasic sarcomatous mesotheliomas should be excluded from
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Sarcomatoid, Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
January 26th, 2007. Survey of surgical treatment of malignant pleural mesothelioma in Japan
086) with a marginal significance, indicating that complete surgical resection of the tumor and perioperative adjuvant therapy could be effective treatment for MPM in Japan. Thus, the development of multimodality therapy including surgical treatment for this disease may be required to improve surgical results of MPM patients.
Posted in Biphasic or Mixed, Chemotherapy, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, General, Pleural, Pleurectomy/decortication, Sarcomatoid, Surgery, Survival, Treatment, Trimodality Therapy, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
December 8th, 2006. Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
Conclusions: CA125 was elevated in the majority of patients with PM in the present series. Serial maker measurements paralleled tumor growth or regression after CRS and IPHP, suggesting the need of further studies to assess the role of CA125 in this clinical setting.
November 30th, 2006. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma
Conclusions: This systematic review evaluated the current evidence for CRS and PIC for DMPM. Seven observational studies were available for assessment, which demonstrated an improved overall survival, as compared to historical controls, using systemic chemotherapy and palliative surgery.
Posted in Chemotherapy, Determining Efficacy, Diffuse mesothelioma, Full Archive, Intraperitoneal Chemotherapy, Peritoneal (Abdominal Mesothelioma), Surgery, Survival, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
November 2nd, 2006. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma
Conclusions: Histomorphologic parameters carry prognostic significance in predicting the survival of patients with diffuse malignant peritoneal mesothelioma when treated in a standardized fashion using cytoreductive surgery and perioperative intraperitoneal chemotherapy. Nuclear/nucleolar size was found to be a reliable histomorphologic assessment available to assess prognosis in these patients.
October 19th, 2006. Sex difference in diffuse malignant peritoneal mesothelioma
Conclusions: Women with DMPM had better survival. This observation may be related to the favourable clinical and histopathological features associated with women.
|
|  |
